^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    Guardant360 Response™

    Company:
    Guardant Health
    Type:
    Laboratory Developed Test
    Related tests:
    Guardant360 Response™ test represents a breakthrough as the first commercially available, blood-only, liquid biopsy test that detects changes in circulating tumor DNA (ctDNA) levels to provide oncologists an early indication of a patient’s response to treatment.
    Cancer:
    Bladder Cancer, Breast Cancer, Gastric Cancer, Non Small Cell Lung Cancer
    Drug:
    Gilotrif (afatinib), Imfinzi (durvalumab), Keytruda (pembrolizumab), Lorbrena (lorlatinib)
    Method:
    Next-Generation Sequencing (NGS) / Circulating Tumor DNA (ctDNA)